Experimental Treatments for Epidermolysis Bullosa
FCX-007
FCX-007 is being developed to treat recessive dystrophic epidermolysis bullosa. It is a cell-based therapy that genetically modifies a patient’s own skin cells to produce healthy copies of type 7 collagen. It is currently being tested in an ongoing Phase 1/2 trial.
SD-101
SD-101 is an experimental cream that is applied to the whole body to promote wound healing in people with epidermolysis bullosa. It has been evaluated in Phase 2b and Phase 3 clinical trials.